Bcl-2 and Bcl-xL enhanced the drug resistance of mesothelioma and laryngeal cancer cells because their down-regulation and Bcl-2 inhibitor (HA14-1) increased the cytotoxic effects of cisplatin, gemcitabine, or the combined treatment with 4625 and cisplatin [9]. Here, BCL2 is linked to mesothelioma.